Calliditas Therapeutics AB
Industry
- Biotechnology
- Pharmaceuticals
- Vaccines
- Specialty Pharmaceuticals
Other Names/Subsidiaries
- Calliditas Therapeutics Suisse
- Genkyotex
- Pharmalink AB
Latest on Calliditas Therapeutics AB
Although Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it
In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to seg
Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm